KR102037502B1 - 고체 상태 형태의 융합된 헤테로아로마틱 피롤리디논 - Google Patents

고체 상태 형태의 융합된 헤테로아로마틱 피롤리디논 Download PDF

Info

Publication number
KR102037502B1
KR102037502B1 KR1020177019929A KR20177019929A KR102037502B1 KR 102037502 B1 KR102037502 B1 KR 102037502B1 KR 1020177019929 A KR1020177019929 A KR 1020177019929A KR 20177019929 A KR20177019929 A KR 20177019929A KR 102037502 B1 KR102037502 B1 KR 102037502B1
Authority
KR
South Korea
Prior art keywords
compound
certain embodiments
cancer
shows
lymphoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177019929A
Other languages
English (en)
Korean (ko)
Other versions
KR20170095374A (ko
Inventor
롱리앙 첸
토모노리 이치바카세
춘롱 마
크리스토퍼 매튜스
하지메 모토요시
콜린 오브라이언
켄타로 야지
나오키 요시카와
Original Assignee
다케다 야쿠힌 고교 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55299676&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102037502(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 다케다 야쿠힌 고교 가부시키가이샤 filed Critical 다케다 야쿠힌 고교 가부시키가이샤
Publication of KR20170095374A publication Critical patent/KR20170095374A/ko
Application granted granted Critical
Publication of KR102037502B1 publication Critical patent/KR102037502B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
KR1020177019929A 2014-12-18 2015-12-17 고체 상태 형태의 융합된 헤테로아로마틱 피롤리디논 Active KR102037502B1 (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201462093564P 2014-12-18 2014-12-18
US62/093,564 2014-12-18
US201562115223P 2015-02-12 2015-02-12
US62/115,223 2015-02-12
US201562180222P 2015-06-16 2015-06-16
US62/180,222 2015-06-16
PCT/IB2015/002489 WO2016097862A2 (en) 2014-12-18 2015-12-17 Solid state forms of fused heteroaromatic pyrrolidinones

Publications (2)

Publication Number Publication Date
KR20170095374A KR20170095374A (ko) 2017-08-22
KR102037502B1 true KR102037502B1 (ko) 2019-10-28

Family

ID=55299676

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177019929A Active KR102037502B1 (ko) 2014-12-18 2015-12-17 고체 상태 형태의 융합된 헤테로아로마틱 피롤리디논

Country Status (29)

Country Link
US (3) US10676473B2 (https=)
EP (2) EP3677582B1 (https=)
JP (3) JP6778195B2 (https=)
KR (1) KR102037502B1 (https=)
CN (1) CN107108609B (https=)
AU (1) AU2015365580B2 (https=)
BR (1) BR112017013149B1 (https=)
CA (1) CA2970864C (https=)
CL (1) CL2017001561A1 (https=)
CO (1) CO2017005910A2 (https=)
CR (1) CR20170249A (https=)
DK (1) DK3233857T3 (https=)
DO (1) DOP2017000130A (https=)
EA (1) EA032291B1 (https=)
EC (1) ECSP17038100A (https=)
ES (1) ES2788454T3 (https=)
GE (2) GEAP201914545A (https=)
IL (1) IL252941B (https=)
MX (1) MX373586B (https=)
MY (1) MY199935A (https=)
NZ (1) NZ732371A (https=)
PE (1) PE20171179A1 (https=)
PH (1) PH12017501123A1 (https=)
PL (1) PL3233857T3 (https=)
SG (1) SG11201701911QA (https=)
TN (1) TN2017000080A1 (https=)
UA (1) UA120632C2 (https=)
WO (1) WO2016097862A2 (https=)
ZA (1) ZA201701800B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY199935A (en) * 2014-12-18 2023-11-29 Wells Therapeutics Inc Solid state forms of fused heteroaromatic pyrrolidinones
WO2018013239A1 (en) * 2016-07-13 2018-01-18 Takeda Pharmaceutical Company Limited Combination of spleen tyrosine kinase inhibitors and other therapeutic agents
CA3079292A1 (en) 2017-10-19 2019-04-25 Bayer Animal Health Gmbh Use of fused heteroaromatic pyrrolidones for treatment and prevention of diseases in animals
WO2019088039A1 (en) 2017-10-30 2019-05-09 Takeda Pharmaceutical Company Limited Treatment of acute myeloid leukemia
MY208604A (en) * 2018-12-14 2025-05-20 Chia Tai Tianqing Pharmaceutical Group Co Ltd Salt of syk inhibitor and crystalline form thereof
JP2022519383A (ja) 2019-02-07 2022-03-23 ヤンセン バイオテツク，インコーポレーテツド ジヒドロオロト酸デヒドロゲナーゼ阻害剤
TW202104207A (zh) 2019-04-17 2021-02-01 美商健生生物科技公司 二氫乳清酸脫氫酶抑制劑
WO2021070132A1 (en) 2019-10-10 2021-04-15 Janssen Biotech, Inc. Bi-aryl dihydroorotate dehydrogenase inhibitors
JP7554829B2 (ja) 2019-12-19 2024-09-20 ヤンセン ファーマシューティカ エヌ．ベー． 置換直鎖スピロ誘導体
WO2022074534A1 (en) 2020-10-05 2022-04-14 Janssen Biotech, Inc. Combinations of dihydroorotate dehydrogenase inhibitors and hypomethylating agents
WO2022127753A1 (zh) * 2020-12-18 2022-06-23 山东轩竹医药科技有限公司 稠环类AhR抑制剂
MX2023013436A (es) 2021-05-11 2023-12-12 Janssen Pharmaceutica Nv Terapias de combinacion.
KR20240006631A (ko) 2021-05-11 2024-01-15 얀센 파마슈티카 엔브이 조합 요법
KR102539612B1 (ko) 2021-12-24 2023-06-02 엘에스일렉트릭(주) IP 기반 RAPIEnet을 지원하는 통신 디바이스 및 이를 포함하는 네트워크 시스템
CN120322230A (zh) 2022-11-30 2025-07-15 詹森药业有限公司 包含多发性内分泌癌蛋白-mll抑制剂和至少一种其他治疗剂的组合
EP4626427A1 (en) 2022-11-30 2025-10-08 Janssen Pharmaceutica NV Combinations comprising a menin-mll inhibitor and a bcl-2 inhibitor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5400388B2 (ja) * 2005-12-15 2014-01-29 ライジェル ファーマシューティカルズ， インコーポレイテッド キナーゼインヒビターおよびその利用
SG181857A1 (en) 2009-12-23 2012-07-30 Takeda Pharmaceutical Fused heteroaromatic pyrrolidinones as syk inhibitors
JP6026525B2 (ja) * 2011-06-22 2016-11-16 武田薬品工業株式会社 置換６−アザ−イソインドリン−１−オン誘導体
TW201625263A (zh) * 2014-09-24 2016-07-16 千禧製藥公司 利用ＰＩ３Ｋα抑制劑與紫杉烷之組合治療
MY199935A (en) * 2014-12-18 2023-11-29 Wells Therapeutics Inc Solid state forms of fused heteroaromatic pyrrolidinones

Also Published As

Publication number Publication date
EP3677582B1 (en) 2023-01-25
DOP2017000130A (es) 2017-07-15
ES2788454T3 (es) 2020-10-21
US11352355B2 (en) 2022-06-07
PL3233857T3 (pl) 2020-07-27
JP6974534B2 (ja) 2021-12-01
AU2015365580B2 (en) 2020-04-02
MX2017007162A (es) 2017-08-28
HK1243406A1 (zh) 2018-07-13
IL252941A0 (en) 2017-08-31
CN107108609A (zh) 2017-08-29
DK3233857T3 (da) 2020-04-27
ZA201701800B (en) 2020-05-27
BR112017013149A2 (pt) 2018-04-10
IL252941B (en) 2020-11-30
MY199935A (en) 2023-11-29
EA032291B1 (ru) 2019-05-31
AU2015365580A1 (en) 2017-07-06
WO2016097862A3 (en) 2016-08-11
CN107108609B (zh) 2020-02-18
EP3233857A2 (en) 2017-10-25
US20200339573A1 (en) 2020-10-29
CA2970864C (en) 2020-04-14
CA2970864A1 (en) 2016-06-23
JP2017537969A (ja) 2017-12-21
US20230348461A1 (en) 2023-11-02
JP2020143081A (ja) 2020-09-10
WO2016097862A2 (en) 2016-06-23
CL2017001561A1 (es) 2018-01-12
GEAP201914545A (en) 2019-08-12
SG11201701911QA (en) 2017-04-27
UA120632C2 (uk) 2020-01-10
CR20170249A (es) 2017-09-25
TN2017000080A1 (en) 2018-07-04
US10676473B2 (en) 2020-06-09
EA201791369A1 (ru) 2017-10-31
EP3677582A1 (en) 2020-07-08
CO2017005910A2 (es) 2017-10-20
JP2022017477A (ja) 2022-01-25
EP3233857B1 (en) 2020-03-11
JP6778195B2 (ja) 2020-10-28
ECSP17038100A (es) 2017-12-01
PE20171179A1 (es) 2017-08-22
PH12017501123A1 (en) 2017-11-27
NZ732371A (en) 2023-04-28
GEP20197050B (en) 2019-12-10
US20160176869A1 (en) 2016-06-23
MX373586B (es) 2020-05-05
KR20170095374A (ko) 2017-08-22
BR112017013149B1 (pt) 2022-10-11

Similar Documents

Publication Publication Date Title
KR102037502B1 (ko) 고체 상태 형태의 융합된 헤테로아로마틱 피롤리디논
ES2704525T3 (es) Derivados de naftiridina como antagonistas de integrina AlfaVBeta6 para el tratamiento de, por ejemplo, enfermedades fibróticas
CN111148745B (zh) Fgfr抑制剂的结晶形式及其制备方法
KR20220101664A (ko) Pd-1/pd-l1 억제제의 염 및 결정질 형태
KR20190119579A (ko) 아르기나제 활성을 억제시키기 위한 조성물 및 방법
HK1204623A1 (en) New phosphate compounds, a process for their preparation and pharmaceutical compositions containing them
CA2849340A1 (en) Pyrazolo[4,3-c]pyridine derivatives as kinase inhibitors
CA2995909A1 (en) Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors
WO2015110092A1 (zh) 4-取代吡咯并[2,3-d]嘧啶化合物及其用途
AU2017304103A1 (en) Cyclic peptides as C5 a receptor antagonists
CN110896636B (zh) 抑制mps1激酶的化合物的盐、其制备以及包含它的制剂
HK40033008B (en) Solid state forms of fused heteroaromatic pyrrolidinones
HK40033008A (en) Solid state forms of fused heteroaromatic pyrrolidinones
JP2024514532A (ja) 大環状アゾロピリジン
HK1243406B (zh) 稠合杂芳族吡咯烷酮的固态形式
HK40022862B (en) Salt of a compound inhibiting mps1 kinase, its preparation and formulations containing it
HK40022862A (en) Salt of a compound inhibiting mps1 kinase, its preparation and formulations containing it
HK40000399A (en) Crystalline forms of n-[2-(3-hydroxy-3-methylbutyl)-6-(2-hydroxypropan-2-yl)-2h-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20220915

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-5-5-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000